The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

REGISTER for free or LOG IN to view this content

Become a GOLD or PLATINUM member to access PowerPoint files, presentation audio, and video

AEGIS-I Trial: The Safety and Tolerability of CSL112

We Recommend